Finally, we identified and validated that Birc5 expression might serve as a prognostic biomarker associated with the infiltration of immune‐suppressive myeloid‐derived suppressor cells (MDSCs) and a promising therapeutic target for HCC patients. Here, BIRC5 is linked to hepatocellular carcinoma.